Skip to main
CDTX
CDTX logo

Cidara Therapeutics (CDTX) Stock Forecast & Price Target

Cidara Therapeutics (CDTX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 59%
Buy 35%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Cidara Therapeutics Inc is positioned favorably due to a strong influenza season reported by the CDC, which indicates a sustained high demand for therapeutic options like CD388. The company has effectively secured funding of $240 million, enabling continued clinical development and rapid progression of CD388, which is perceived to have superiority over traditional vaccines as it does not rely on the immune system. These factors collectively highlight a promising uptake potential for CD388, supported by significant clinical data, which may lead to improved financial performance for the company in the upcoming periods.

Bears say

Cidara Therapeutics reported a significant net loss of $52.4 million for the fourth quarter of 2024, translating to a loss of $5.38 per share, highlighting ongoing financial challenges. The company's lead asset, CD388, despite its strong potency against influenza A and B, suffers from poor oral bioavailability and rapid renal clearance, raising concerns over its clinical usability. Additionally, Cidara's lack of a proven track record of profitability, combined with the potential for future candidates to fail in meeting efficacy and safety benchmarks, further exacerbates the uncertainties surrounding its commercial viability.

Cidara Therapeutics (CDTX) has been analyzed by 17 analysts, with a consensus rating of Buy. 59% of analysts recommend a Strong Buy, 35% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cidara Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cidara Therapeutics (CDTX) Forecast

Analysts have given Cidara Therapeutics (CDTX) a Buy based on their latest research and market trends.

According to 17 analysts, Cidara Therapeutics (CDTX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cidara Therapeutics (CDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.